title: Cell kinetic measurements in prostate cancer.
abstract: OBJECTIVE
  Two approaches have been suggested for escalating the total dose in radiotherapy treatment of prostate cancer. One is conformal radiotherapy; the other is hyperfractionation using many small fractions. Both imply some possible prolongation in overall treatment time. To judge whether prolonged treatment schedules would be detrimental, it is necessary to know the proliferation rates in human prostate tumors, specifically, the potential doubling time (Tpot). There is a lack of data on this parameter in the literature.
  
  
  METHODS
  Seven patients with adenocarcinoma of the prostate were studied. A tracer dose of 100 mg/m2 of IUdR was infused intravenously 4-12 h before biopies were taken. Biopsies were fixed in 70% ethanol, stored at 4 degrees C, and later prepared and stained by standard methods for flow cytometry, using the red fluorescence signal for DNA and the green fluorescence signal (fluorescein isothiocyanate) for 5-iodo-2'-deoxyuridine. The duration of DNA synthesis (Ts) was determined by the relative movement (RM) method, knowing the interval between tracer administration and biopsy. Tpot was calculated as the quotient of Ts by labeling index (LI).
  
  
  RESULTS
  In two of the seven tumors the LI was too low (<0.6%) for a reliable estimate of RM to be made, so no determination of Tpot was possible for these tumors. The mean LI values in the other five tumors were 2.4%, 1.4%, 1.0%, 3.0%, and 0.9%. The durations of Ts were 13.2, 9.5, 10.0, 11.7, and 12.7 h, respectively. The resulting values of Tpot were 23, 28, 42, 16, and 61 days, respectively.
  
  
  CONCLUSIONS
  The low labeling indices in prostate tumors, also reported by others, made estimation of Ts by RM impossible in about a third of these tumors. However, five tumors yielded long estimates for Tpot, implying that prolongation from 6 to about 8 weeks should not be detrimental.
authors.affiliation: Department of Radiotherapy, University Hospital, Leuven, Belgium.
authors.forename: K M
authors.initials: KM
authors.lastname: Haustermans
authors.forename: I
authors.initials: I
authors.lastname: Hofland
authors.forename: H
authors.initials: H
authors.lastname: Van Poppel
authors.forename: R
authors.initials: R
authors.lastname: Oyen
authors.forename: W
authors.initials: W
authors.lastname: Van de Voorde
authors.forename: A C
authors.initials: AC
authors.lastname: Begg
authors.forename: J F
authors.initials: JF
authors.lastname: Fowler
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology* / Q000532:radiotherapy; D001706:Biopsy; D002455:Cell Division / Q000235:genetics / Q000502:physiology*; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D011467:Prostate / Q000473:pathology*; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000532:radiotherapy